| 21-757 |
Amgen Inc., et al. v. Sanofi, et al. |
Federal Circuit |
2021-11-22 |
Judgment Issued |
35-usc-112 claim-construction claim-scope enablement enablement-requirement invention-disclosure judicial-review patent patent-law statutory-interpretation undue-experimentation written-description |
Whether enablement is a question of fact or law |
| 20-74 |
Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director, United States Patent and Trademark Office v. Eugene H. Luoma, et al. |
Federal Circuit |
2020-07-27 |
GVR |
administrative-law america-invents-act enablement intellectual-property judicial-review obviousness patent-eligibility patent-review patent-trial-and-appeal-board patent-validity prior-art written-description |
Whether the Patent Trial and Appeal Board's application of the statutory requirements for patentability under 35 U.S.C. §§ 101, 102, 103, and 112 was … |
| 18-127 |
Amgen Inc., et al. v. Sanofi, et al. |
Federal Circuit |
2018-07-27 |
Denied |
35-usc-112 biotechnology enablement federal-circuit innovation patent-law possession statutory-interpretation written-description |
Whether the standard for determining the adequacy of the 'written description of the invention' should be as the statute says—that the description mus… |